Clinicians Wait for Next Wave of Hepatitis C Antivirals - By: Debra Gordon
"It’s been just two years since the protease-inhibitors boceprevir (Victrelis) and telaprevir (Incivek), the first in what was described as a “disease-changing” class of drugs for the treatment of hepatitis C (HCV), were approved. Yet many clinicians already consider the original directly acting antivirals (DAAs) obsolete.Although clinical trials showed they increase the cure rate from the 50% seen with the standard of care peginterferon-alpha (PEG-IFN) and ribavirin(Drug information on ribavirin) (RBV), to about 75% in patients chronically infected with HCV-1, their high rate of adverse effects, high pill burden, drug-drug interactions, low response in certain populations, and the need to administer them in conjunction with PEG-IFN and RBV has significantly limited their use.1 The reality is that clinicians are abandoning the drugs as they wait for the first in a new wave of HCV therapies expected to hit the market in late 2013 and 2014."
To read the full article, please visit: http://www.theaidsreader.com/display/article/1145619/2145963
1300 Wilson Boulevard | Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200 | Fax: (703) 299-0204
| HIVMA | Contact Us
© Copyright IDSA 2013 Infectious Diseases Society of America